Home › Companies › Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc. (RNAC) proxy voting records
How asset managers voted at Cartesian Therapeutics, Inc.’s shareholder meetings, one page per
proxy season, compiled from the votes funds and managers report on SEC Form N-PX and
the company’s own results on Form 8-K.
- TickerRNAC
- CUSIP issuer number816212
- SEC CIK1453687
Recent shareholder votes
- June 12, 2026 annual meeting (2025-2026 proxy season): 5 items in Cartesian Therapeutics, Inc.'s official results (Form 8-K, filed June 17, 2026); lowest support 59% of votes cast (Elect Director: Michael Singer, M.D., Ph.D.). Full results and how funds voted.
- June 13, 2025 annual meeting (2024-2025 proxy season): 5 items in Cartesian Therapeutics, Inc.'s official results (Form 8-K, filed June 16, 2025); lowest support 97% of votes cast (Elect Director: Timothy C. Barabe, M.B.A.). Full results and how funds voted.
- September 20, 2024 special meeting (2024-2025 proxy season): 2 items in Cartesian Therapeutics, Inc.'s official results (Form 8-K, filed September 23, 2024); lowest support 99% of votes cast (Approval of the issuance of shares of the Company's Common…). Full results and how funds voted.
- June 14, 2024 annual meeting (2023-2024 proxy season): 5 items in Cartesian Therapeutics, Inc.'s official results (Form 8-K, filed June 17, 2024); lowest support 93% of votes cast (Approval of the Cartesian Therapeutics, Inc. Amended and…). Full results and how funds voted.
Each line is the company’s own Form 8-K tally as shown on that season’s page; support is FOR as a share of votes cast.
Proxy seasons
Earlier seasons list this company under the name
CARTESIAN THERAPEUTICS INC., as its holders filed it.
Explore Cartesian Therapeutics, Inc. in the interactive database
The seasons are grouped by the issuer number in the company’s CUSIP, not by
its name. Ticker as listed by the SEC on November 6, 2026.
This page is rebuilt weekly; built November 9, 2026.